CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
Main Article Content
Keywords
Hepatocellular carcinoma, Thalassemias, Risk factors, Surveillance
Abstract
Due to the recent alarming increase in the incidence of hepatocellular carcinoma (HCC) in thalassemias, the aim of the present report is to review briefly the frequency, the major risk factors and the surveillance of HCC in ?-thalassemias. Over the past 33 years, 153 cases of HCC were reported in patients with thalassemia, mainly in Italy, and Greece. Among HCV-infected patients additional factors promoting development of HCC, included: advanced age, male sex, chronic hepatitis B (CHB) coinfection, and iron overload. For early diagnosis of HCC sequential ultrasound screening is recommended especially for thalassemia patients with chronic hepatitis C (CHC), that coincide with (one or more) additional risk factors for HCC. Here we report also the preliminary data of thalassemic patients, above the age of 30 years, followed in 13 different centers. The total number of enrolled patients was 1,313 (males: 612 and 701 females). The prevalence of HCC in thalassemia major patients [characterized by transfusion-dependency (TDT)] and thalassemia intermedia [characterized by nontransfusion dependency (NTDT)] was 1.68 % and 1.98 % ,respectively The lowest age at diagnosis was 36 years in TDT and 47 years in NTDT patients.We hope that our review can be used to develop more refined and prospective analyses of HCC magnitude and risk in patients with thalassemia, and to define specific international guidelines to support clinicians for an early diagnosis and treatment of HCC in thalassemic patients.
Downloads
Download data is not yet available.
Abstract 3574
PDF Downloads 1223
HTML Downloads 229
References
1. Shiani A, Narayanan S, Pena L, Friedman M. The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer. Cancer Control. 2017 Jul-Sep;24 (3): 10732748 177 29240. doi: 10.1177/1073274817729240.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
3. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin S, Hamid SS, Modawi SB, Fleig W, Fedail S, Thomson A, Khan A, Malfertheiner P, Lau G, Carillo FJ, Krabshuis J, Le Mair A; World Gastroenterology Organization. World Gastroenterology Organisation guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis. 2010;19:311–317.
4. Darbari A, Sabin KM, Shapiro CN, Schwarz KB.Epidemiology of primary hepatic malignancies in U.S. children. Hepatology. 2003;38:560–566.
5. Liu P, Xie SH, Hu S, Cheng X, Gao T, Zhang C, Song Z. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States, Oncotarget. 2017 Jul 12;8(40):68131-68137. doi: 10.18632/oncotarget.19245.
6.Bruix, J,Sherman M, American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma: An Update. Hepatology.2011;53:1020-1022.
7.European Association for the Study of The Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J Hepatol.2012;56:908-943.
8. Mokdad AA, Hester CA, Singal AG, Yopp AC. Management of hepatocellular in the United States. Chin Clin Oncol. 2017 Apr;6(2):21.doi: 10.21037/cco.2017.04.04.
9.Bettinger D, Spode R, Glaser N, Buettner N, Boettler T, Neumann-Haefelin C, Brunner TB, Gkika E, Maruschke L, Thimme R, Schultheiss M. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. BMC Gastroenterol. 2017 Aug 10;17(1):98. doi: 10.1186/s12876-017-0656-z
10. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population, J Clin Gastroenterol. 2013;47 (Suppl) :S2-6.
11. Kourakli A, Diamantidis MD, Skafidas ME, Delicou S, Pantelidou D, Fragodimitri C, Vlachaki E, Lafioniatis S, Petropoulou F, Eftychiadis E, Kapsali E, Kalpaka A, Zissis C, Koutsouka F, Vasileiadi A, Goula A, Giasari P, Katsatou M, Lafiatis I, Klironomos E, Kaiafas P, Kyriacopoulou D, Lazaris V, Maragkos K, Fotiou P, Chalkia P, Schiza V, Kattamis A, Symeonidis A. Hepatitis C Virus Infection, but Not Hepatic Iron Overload Is the Dominant Risk Factor for the Manifestation of Hepatocellular Carcinoma Among Greek Thalassemic Patients.Blood. 2018 132:2347; doi: https://doi.org/10.1182/blood-2018-99-119731.
12. Borgna-Pignatti C, De Stefano P, Sessa F, Avato F. Hepatocellular carcinoma in thalassemia major. Med Pediatr Oncol.1986;14:327–328.
13. Zurlo M, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassaemia major. Lancet. 1989;334:27–30.
14. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124:114–117.
15. Mancuso A, Rigano P, Renda D, Maggio A. Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic. Am J Hematol.2005;78:158–159.
16. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin. 2006:30:119–124.
17. Restivo Pantalone G, Renda D, Valenza F, D'Amato F,Vitrano A, Cassarà F, Rigano P, Di Salvo V, Giangreco A, Bevacqua E, Maggio A. Hepatocellular carcinoma in patients with thalassaemia syndromes: Clinical characteristics and outcome in a long term single centre experience. Br J Haematol. 2010;150:245–247.
18. Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit.Hemoglobin. 2010: 34:221–226.
19. Ansari S, Azarkivan A, Halagi F. Incidence of hepatocellular carcinoma in patients with thalassemia who had hepatitis C. Acta Med Iran. 2013;51:404–407.
20. Maakaron JE, Cappellini MD, Graziadei G, Ayache JB, Taher AT. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis. Ann Hepatol. 2013;12:142–146.
21. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance [serial online].
J Cardiovasc Magn Reson. 2008;10:42. doi: 10.1186/1532-429X-10-42.
22. Borgna-Pignatti C, Garani MC, Forni GL, Cappellini MD, Cassinerio E, Fidone C, Spadola V, Maggio A, Restivo Pantalone G, Piga A, Longo F, Gamberini MR, Ricchi P, Costantini S, D'Ascola D, Cianciulli P, Lai ME, Carta MP, Ciancio A, Cavalli P, Putti MC, Barella S, Amendola G, Campisi S, Capra M, Caruso V, Colletta G, Volpato S.Hepatocellular carcinoma in thalassaemia: An update of the Italian Registry. Br J Haematol. 2014;167:121–126.
23. Moukhadder HM, Roumi JE, Bou-Fakhredin R, Taher AT. Hepatocellular Carcinoma in a ?- Thalassemia Intermedia Patient: Yet Another Case in the Expanding Epidemic. Hemoglobin. 2018; 42:58–60.
24.Haghpanah S, Jelodari S, Karamifar H, Saki F, Rahimi R, De Sanctis V, Dehbozorgian J, Karimi M.
The frequency of hypothyroidism and its relationship with HCV positivity in patients with thalassemia major in southern Iran.Acta Biomed. 2018;89:55-60.
25.Shi L, Feng Y, Lin H, Ma R, Cai X. Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med. 2014 Apr 8;12:93. doi: 10.1186/1479-5876-12-93.
26. Nagasue N, Ito A, Yukaya H, Ogawa Y. Estrogen receptors in hepatocellular carcinoma. Cancer. 1986;57:87–91.
27. Nagasue N, Ito A, Yukaya H, Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology. 1985;89:643–647.
28. Pok S, Barn VA, Wong HJ, Blackburn AC, Board P, Farell GC, Teoh NC. Testosterone regulation of cyclin E kinase: a key factor in determining gender differences in hepatocarcinogenesis. J Gastroenterol Hepatol.2016;31:1210-1219.
29. Chen PJ, Yeh SH, Liu WH, Lin CC, Huang HC, Chen CL, Chen DS, Chen PJ.Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology. 2012;56: 632–643.
30. De Sanctis V, Elsedfy H, Soliman AT, Elhakim IZ, Pepe A, Kattamis C, Soliman NA, Elalaily R, El Kholy M, Yassin M. Acquired Hypogonadotropic Hypogonadism (AHH) in Thalassaemia Major Patients: An Underdiagnosed Condition? Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016001. doi: 10.4084/MJHID.2016.001
31.De Sanctis V, Soliman AT, Daar S, Di Maio S. Adverse events during testosterone replacement therapy in 95 young hypogonadal thalassemic men. Acta Biomed. 2019;90:228-232.
32.Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007;47:506–513.
33. McGlynn KA, Sahasrabuddhe VV, Campbell PT, Graubard BI, Chen J, Schwartz LM, Petrick JL, Alavanja MC, Andreotti G, Boggs DA, Buring JE, Chan AT, Freedman ND, Gapstur SM, Hollenbeck AR, Hou L, King LY, Koshiol J, Linet M, Palmer JR, Poynter JN, Purdue M, Robien K, Schairer C, Sesso HD, Sigurdson A, Wactawski-Wende J, Zeleniuch-Jacquotte A. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer. 2015;112:1266–1272.
34. De Maria N, Manno M, Villa E. Sex hormones and liver cancer. Mol Cell Endocrinol. 2002;193:59–63.
35.Lai ME, Origa R, Danjou F, Leoni GB, Vacquer S, Anni F, Corrias C, Farci P, Congiu G, Galanello R. Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur J Haematol. 2013;90:501-507.
36. Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, Oh JK, Park S, Kim YJ, Shin HR, Yoo KY, Park SK. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2011;128:176–184.
37. El-Serag HB. Hepatocellular Carcinoma and Hepatitis C in the United States. Hepatology. 2002;36:S74–83.
38. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;501142–1154.
39. Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F, Ferraro D, Cuccia L, Ruffo GB, Bronte F, Di Stefano R, Almasio PL, Craxì A. Liver disease in chelated transfusion-dependent thalassemics: The role of iron overload and chronic hepatitis C. Hematologica. 2008;93:1243-1246.
40. Elalfy MS, Esmat G, Matter RM, Abdel Aziz HE, Massoud WA. Liver fibrosis in young Egyptian beta-thalassemia major patients: Relation to hepatitis C virus and compliance with chelation. Ann
Hepatol. 2013;12:54-61.
41. Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F, Ferraro D, Cuccia L, Ruffo GB, Bronte F, Di Stefano R, Almasio PL, Craxì A. Liver disease in chelated transfusion-dependent thalassemics: The role of iron overload and chronic hepatitis C. Hematologica. 2008;93:1243-1246.
42.Maira D, Cassinerio E, Marcon A, Mancarella M, Fraquelli M, Pedrotti P, Cappellini MD. Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT). Ann Hematol. 2017;96:1931-1936.
43. Zachou K, Arvaniti P,Gatselis NK, Azariadis K, Papadamou G, Rigopoulou E, Dalekos GN. Patients with haemoglobinopathies and chronic hepatitis C: a real difficult to treat population in 2016? Mediterr J Hematol Infect Dis. 2017, 9(1): e2017003, DOI: http://dx.doi.org/10.4084/MJHID.2017.003.
44, Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. J Am Med Assoc 2014;312:631-40.
45.Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and futuredirection. J Transl Intern Med 2017;5:8-17.
46. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593–1601.
47. Zamani F, Ajdarkosh H, Safarnezhad-Tameshkel F, Azarkeivan A, Keyvani H, Naserifar F, Vafaeimanesh J. The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors. Indian J Med Microbiol. 2018;36:224-229.
48. Origa R, Ponti ML, Filosa A, Galeota Lanza A, Piga A, Saracco GM, Pinto V, Picciotto A, Rigano P, Madonia S, Rosso R, D'Ascola D, Cappellini MD, D'Ambrosio R, Tartaglione I, De Franceschi L, Gianesin B, Di Marco V, Forni GL; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am J Hematol. 2017;92:1349-1355.
49.Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos C, Vassiliadis T, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, Dalekos GN, Akriviadis E, Papatheodoridis GV. Treatment of chronic hepatitis C with direct-acting antivirals in patients with ?-thalassaemia major and advanced liver disease.Br J Haematol. 2017;178:130-136.
50. Okada S, Hamazaki S, Toyokuni S, Midorikawa O. Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats. British J Cancer. 1989; 60:708-711.
51. Yu Y, Suryo Rahmanto Y, Richardson DR. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. British J Pharmacol. 2012; 165:148-166.
52. Kew MC. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett. 2009;286:38-43.
53. Tirnitz-Parker JE, Glanfield A, Olynyk JK, Ramm GA. Iron and hepatic carcinogenesis. Crit Rev Oncog. 2013; 18:391-407.
54. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127
(5 suppl 1):S79-S86.
55. Kew MC.Hepatic iron overload and hepatocellular carcinoma. Liver Cancer 2014; 3:31-40.
56. Matzner Y, Hershko C, Polliack A, Konijn AM, Izak G. Suppressive effect of ferritin on in vitro lymphocyte function. Br J Haematol.1979;42:345-353.
57. Walker EM, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci. 2000; 30:354-365.
58. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011; 53:1020–1022.
59.Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT.Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. Int J Mol Sci. 2018 Jan 8;19(1). pii: E182. doi: 10.3390/ijms19010182.
60.Finianos A, Matar CF, Taher A. Hepatocellular Carcinoma in ?-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. Int J Mol Sci. 2018 Dec 17;19(12). pii: E4070. doi: 10.3390/ijms19124070
61. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557–2576.
62. Shen FM, Lee MK, Gong HM, Cai XQ, King MC. Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: interaction of inherited susceptibility and hepatitis B viral infection. Am J Hum Genet.1991;49:88–93.
63. Walker AJ, Peacock CJ, Pedergnana V; STOP-HCV Consortium, Irving WL. Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review. J Viral Hepat. 2018;25:442-456.
64. Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal AK. Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and nonalcoholic fatty liver diseases. J Clin Transl Hepatol. 2015;3:9-16.
65.Mowla A, Karimi M, Afrasiabi A, De Sanctis V. Prevalence of diabetes mellitus and impaired glucose tolerance in beta-thalassemia patients with and without hepatitis C virus infection.Pediatr Endocrinol Rev. 2004;2 (Suppl 2):282-824.
66.De Sanctis V, Soliman AT, Elsedfy H, Yaarubi SA, Skordis N, Khater D, El Kholy M, Stoeva I, Fiscina B, Angastiniotis M, Daar S, Kattamis C. The ICET-A Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients Mediterr J Hematol Infect Dis. 2016 Oct 28;8(1):e2016058.
67.Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2012;87:155-160.
68.Wankanit S, Chuansumrit A, Poomthavorn P, Khlairit P, Pongratanakul S, Mahachoklertwattana P.Acute Effects of Blood Transfusion on Insulin Sensitivity and Pancreatic ?-Cell Function in Children with ?-Thalassemia/Hemoglobin E Disease.J Clin Res Pediatr Endocrinol. 2018;10:1-7.
69.Petersen DR. Alcohol, iron-associated oxidative stress, and cancer. Alcohol. 2005;35:243–249.
70.Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S, Chung FL, Tang MS. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis. 2002;23:1781–1789.
71.Barbieri SS, Zacchi E, Amadio P, Gianellini S, Mussoni L, Weksler BB, Tremoli E. Cytokines present in smokers’ serum interact with smoke components to enhance endothelial dysfunction. Cardiovasc Res. 2011;90:475–483.
72.Díez Piña JM, Fernández Aceñero MJ, Llorente Alonso MJ, Díaz Lobato S, Mayoralas Alises S, Pérez Rodríguez E, Alvaro Álvarez D, Flórez Horcajada A, Pérez Rojo R. Tumor necrosis factor as an early marker of inflammation in healthy smokers. Med Clin (Barc). 2012;139:47–53.
73.Valenca SS, Silva Bezerra F, Lopes AA, Romana-Souza B, Marinho Cavalcante MC, Lima AB, Gonçalves Koatz VL, Porto LC. Oxidative stress in mouse plasma and lungs induced by cigarette smoke and lipopolysaccharide. Environ Res. 2008;108:199–204.
74.Purohit V, Rapaka R, Kwon OS, Song BJ. Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma. Life Sci. 2013;92:3-9.
75. Conti F, Buonfiglioli F, Scuteri A , Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727-733.
76. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-Radosalvjevic M, Trauner M, Hofer H, Ferenci P. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol. 2016;65:856-858.
77. Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, Pereira P, Lopes S, Silva M, Andrade P, Morais R, Coelho R, Macedo G. High incidence of hepatocellular carcinoma following successful interferonfree antiviral therapy for hepatitis C associated cirrhosis. J Hepatol. 2016; 65: 1070-1071.
78. Reig M, Mariño Z, Perello C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-726.
79. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol.2016;65:734-740.
80.Adhoute X, Castellani P, Bourlière M. Impact of direct-acting antiviral agents on the risk for
hepatocellular carcinoma. Transl Gastroenterol Hepatol 2017;2:110.doi:10.21037/ tgh.2017. 12.04.
81.Soliman A, De Sanctis V, Yassin M. Vitamin d status in thalassemia major: an update.Mediterr J Hematol Infect Dis. 2013 Sep 2;5(1):e2013057. doi: 10.4084/MJHID.2013.057
82.Wu DB, Wang ML, Chen EQ, Tang H. New insights into the role of vitamin D in hepatocellular carcinoma.Expert Rev Gastroenterol Hepatol. 2018;12:287-294.
83.Louka ML, Fawzy AM, Naiem AM, Elseknedy MF, Abdelhalim AE, Abdelghany MA. Vitamin D and K signaling pathways in hepatocellular carcinoma. Gene. 2017;629:108-116.
84. Chiang KC, Yeh CN, Chen MF, Chen TC. Hepatocellular carcinoma and vitamin D: a review. J Gastroenterol Hepatol. 2011;26:1597-603.
85. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, NakatsuraT. Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. World J Gastroenterol. 2015; 21:10573-10583.
86. Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, Tsubouchi H, Kiyosawa K, Kakumu S, Okita K, Hayashi N, Okanoue T. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–1622.
87..Ryder SD; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003; 52 (Suppl 3):1–8.
88.Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment.Oncologist. 2010;15 (Suppl 4):14-22.
89. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA.Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.
90.Sciancalepore D, Zingaro MT, Luglio CV, Sabba C,Napoli N. Hepatocellular Carcinoma: Known and Emerging Risk Factors. J Cancer Ther. 2018;9:417-437.
91.Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol. 2008;48:848–857.
92. Jo PC, Jang HJ, Burns PN, Burak KW, Kim TK, Wilson SR. Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how i do it. Radiology 2017;282:317- 331.
93. Nakayama Y, Inoue T, Sakamoto M, Enomoto N. Liver stiffness measurement for risk assessment of hepatocellular carcinoma. Hepatol Res. 2015;45:523-532.
94.Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68:723-750.
95.Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M, Giannini EG, Borzio F, Caturelli E, Chiaramonte M, Bernardi M; Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010; 53:291-297.
96.Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography [FibroScan(®)] with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol. 2016;22:7236-7251.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
3. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin S, Hamid SS, Modawi SB, Fleig W, Fedail S, Thomson A, Khan A, Malfertheiner P, Lau G, Carillo FJ, Krabshuis J, Le Mair A; World Gastroenterology Organization. World Gastroenterology Organisation guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis. 2010;19:311–317.
4. Darbari A, Sabin KM, Shapiro CN, Schwarz KB.Epidemiology of primary hepatic malignancies in U.S. children. Hepatology. 2003;38:560–566.
5. Liu P, Xie SH, Hu S, Cheng X, Gao T, Zhang C, Song Z. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States, Oncotarget. 2017 Jul 12;8(40):68131-68137. doi: 10.18632/oncotarget.19245.
6.Bruix, J,Sherman M, American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma: An Update. Hepatology.2011;53:1020-1022.
7.European Association for the Study of The Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J Hepatol.2012;56:908-943.
8. Mokdad AA, Hester CA, Singal AG, Yopp AC. Management of hepatocellular in the United States. Chin Clin Oncol. 2017 Apr;6(2):21.doi: 10.21037/cco.2017.04.04.
9.Bettinger D, Spode R, Glaser N, Buettner N, Boettler T, Neumann-Haefelin C, Brunner TB, Gkika E, Maruschke L, Thimme R, Schultheiss M. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience. BMC Gastroenterol. 2017 Aug 10;17(1):98. doi: 10.1186/s12876-017-0656-z
10. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population, J Clin Gastroenterol. 2013;47 (Suppl) :S2-6.
11. Kourakli A, Diamantidis MD, Skafidas ME, Delicou S, Pantelidou D, Fragodimitri C, Vlachaki E, Lafioniatis S, Petropoulou F, Eftychiadis E, Kapsali E, Kalpaka A, Zissis C, Koutsouka F, Vasileiadi A, Goula A, Giasari P, Katsatou M, Lafiatis I, Klironomos E, Kaiafas P, Kyriacopoulou D, Lazaris V, Maragkos K, Fotiou P, Chalkia P, Schiza V, Kattamis A, Symeonidis A. Hepatitis C Virus Infection, but Not Hepatic Iron Overload Is the Dominant Risk Factor for the Manifestation of Hepatocellular Carcinoma Among Greek Thalassemic Patients.Blood. 2018 132:2347; doi: https://doi.org/10.1182/blood-2018-99-119731.
12. Borgna-Pignatti C, De Stefano P, Sessa F, Avato F. Hepatocellular carcinoma in thalassemia major. Med Pediatr Oncol.1986;14:327–328.
13. Zurlo M, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, Di Gregorio F, Burattini MG, Terzoli S. Survival and causes of death in thalassaemia major. Lancet. 1989;334:27–30.
14. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124:114–117.
15. Mancuso A, Rigano P, Renda D, Maggio A. Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic. Am J Hematol.2005;78:158–159.
16. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin. 2006:30:119–124.
17. Restivo Pantalone G, Renda D, Valenza F, D'Amato F,Vitrano A, Cassarà F, Rigano P, Di Salvo V, Giangreco A, Bevacqua E, Maggio A. Hepatocellular carcinoma in patients with thalassaemia syndromes: Clinical characteristics and outcome in a long term single centre experience. Br J Haematol. 2010;150:245–247.
18. Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit.Hemoglobin. 2010: 34:221–226.
19. Ansari S, Azarkivan A, Halagi F. Incidence of hepatocellular carcinoma in patients with thalassemia who had hepatitis C. Acta Med Iran. 2013;51:404–407.
20. Maakaron JE, Cappellini MD, Graziadei G, Ayache JB, Taher AT. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: A closer look at the role of siderosis. Ann Hepatol. 2013;12:142–146.
21. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance [serial online].
J Cardiovasc Magn Reson. 2008;10:42. doi: 10.1186/1532-429X-10-42.
22. Borgna-Pignatti C, Garani MC, Forni GL, Cappellini MD, Cassinerio E, Fidone C, Spadola V, Maggio A, Restivo Pantalone G, Piga A, Longo F, Gamberini MR, Ricchi P, Costantini S, D'Ascola D, Cianciulli P, Lai ME, Carta MP, Ciancio A, Cavalli P, Putti MC, Barella S, Amendola G, Campisi S, Capra M, Caruso V, Colletta G, Volpato S.Hepatocellular carcinoma in thalassaemia: An update of the Italian Registry. Br J Haematol. 2014;167:121–126.
23. Moukhadder HM, Roumi JE, Bou-Fakhredin R, Taher AT. Hepatocellular Carcinoma in a ?- Thalassemia Intermedia Patient: Yet Another Case in the Expanding Epidemic. Hemoglobin. 2018; 42:58–60.
24.Haghpanah S, Jelodari S, Karamifar H, Saki F, Rahimi R, De Sanctis V, Dehbozorgian J, Karimi M.
The frequency of hypothyroidism and its relationship with HCV positivity in patients with thalassemia major in southern Iran.Acta Biomed. 2018;89:55-60.
25.Shi L, Feng Y, Lin H, Ma R, Cai X. Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med. 2014 Apr 8;12:93. doi: 10.1186/1479-5876-12-93.
26. Nagasue N, Ito A, Yukaya H, Ogawa Y. Estrogen receptors in hepatocellular carcinoma. Cancer. 1986;57:87–91.
27. Nagasue N, Ito A, Yukaya H, Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology. 1985;89:643–647.
28. Pok S, Barn VA, Wong HJ, Blackburn AC, Board P, Farell GC, Teoh NC. Testosterone regulation of cyclin E kinase: a key factor in determining gender differences in hepatocarcinogenesis. J Gastroenterol Hepatol.2016;31:1210-1219.
29. Chen PJ, Yeh SH, Liu WH, Lin CC, Huang HC, Chen CL, Chen DS, Chen PJ.Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology. 2012;56: 632–643.
30. De Sanctis V, Elsedfy H, Soliman AT, Elhakim IZ, Pepe A, Kattamis C, Soliman NA, Elalaily R, El Kholy M, Yassin M. Acquired Hypogonadotropic Hypogonadism (AHH) in Thalassaemia Major Patients: An Underdiagnosed Condition? Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016001. doi: 10.4084/MJHID.2016.001
31.De Sanctis V, Soliman AT, Daar S, Di Maio S. Adverse events during testosterone replacement therapy in 95 young hypogonadal thalassemic men. Acta Biomed. 2019;90:228-232.
32.Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007;47:506–513.
33. McGlynn KA, Sahasrabuddhe VV, Campbell PT, Graubard BI, Chen J, Schwartz LM, Petrick JL, Alavanja MC, Andreotti G, Boggs DA, Buring JE, Chan AT, Freedman ND, Gapstur SM, Hollenbeck AR, Hou L, King LY, Koshiol J, Linet M, Palmer JR, Poynter JN, Purdue M, Robien K, Schairer C, Sesso HD, Sigurdson A, Wactawski-Wende J, Zeleniuch-Jacquotte A. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer. 2015;112:1266–1272.
34. De Maria N, Manno M, Villa E. Sex hormones and liver cancer. Mol Cell Endocrinol. 2002;193:59–63.
35.Lai ME, Origa R, Danjou F, Leoni GB, Vacquer S, Anni F, Corrias C, Farci P, Congiu G, Galanello R. Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur J Haematol. 2013;90:501-507.
36. Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, Oh JK, Park S, Kim YJ, Shin HR, Yoo KY, Park SK. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2011;128:176–184.
37. El-Serag HB. Hepatocellular Carcinoma and Hepatitis C in the United States. Hepatology. 2002;36:S74–83.
38. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009;501142–1154.
39. Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F, Ferraro D, Cuccia L, Ruffo GB, Bronte F, Di Stefano R, Almasio PL, Craxì A. Liver disease in chelated transfusion-dependent thalassemics: The role of iron overload and chronic hepatitis C. Hematologica. 2008;93:1243-1246.
40. Elalfy MS, Esmat G, Matter RM, Abdel Aziz HE, Massoud WA. Liver fibrosis in young Egyptian beta-thalassemia major patients: Relation to hepatitis C virus and compliance with chelation. Ann
Hepatol. 2013;12:54-61.
41. Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F, Ferraro D, Cuccia L, Ruffo GB, Bronte F, Di Stefano R, Almasio PL, Craxì A. Liver disease in chelated transfusion-dependent thalassemics: The role of iron overload and chronic hepatitis C. Hematologica. 2008;93:1243-1246.
42.Maira D, Cassinerio E, Marcon A, Mancarella M, Fraquelli M, Pedrotti P, Cappellini MD. Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT). Ann Hematol. 2017;96:1931-1936.
43. Zachou K, Arvaniti P,Gatselis NK, Azariadis K, Papadamou G, Rigopoulou E, Dalekos GN. Patients with haemoglobinopathies and chronic hepatitis C: a real difficult to treat population in 2016? Mediterr J Hematol Infect Dis. 2017, 9(1): e2017003, DOI: http://dx.doi.org/10.4084/MJHID.2017.003.
44, Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. J Am Med Assoc 2014;312:631-40.
45.Geddawy A, Ibrahim YF, Elbahie NM, Ibrahim MA. Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and futuredirection. J Transl Intern Med 2017;5:8-17.
46. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593–1601.
47. Zamani F, Ajdarkosh H, Safarnezhad-Tameshkel F, Azarkeivan A, Keyvani H, Naserifar F, Vafaeimanesh J. The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors. Indian J Med Microbiol. 2018;36:224-229.
48. Origa R, Ponti ML, Filosa A, Galeota Lanza A, Piga A, Saracco GM, Pinto V, Picciotto A, Rigano P, Madonia S, Rosso R, D'Ascola D, Cappellini MD, D'Ambrosio R, Tartaglione I, De Franceschi L, Gianesin B, Di Marco V, Forni GL; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. Am J Hematol. 2017;92:1349-1355.
49.Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos C, Vassiliadis T, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, Dalekos GN, Akriviadis E, Papatheodoridis GV. Treatment of chronic hepatitis C with direct-acting antivirals in patients with ?-thalassaemia major and advanced liver disease.Br J Haematol. 2017;178:130-136.
50. Okada S, Hamazaki S, Toyokuni S, Midorikawa O. Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats. British J Cancer. 1989; 60:708-711.
51. Yu Y, Suryo Rahmanto Y, Richardson DR. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. British J Pharmacol. 2012; 165:148-166.
52. Kew MC. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett. 2009;286:38-43.
53. Tirnitz-Parker JE, Glanfield A, Olynyk JK, Ramm GA. Iron and hepatic carcinogenesis. Crit Rev Oncog. 2013; 18:391-407.
54. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology. 2004;127
(5 suppl 1):S79-S86.
55. Kew MC.Hepatic iron overload and hepatocellular carcinoma. Liver Cancer 2014; 3:31-40.
56. Matzner Y, Hershko C, Polliack A, Konijn AM, Izak G. Suppressive effect of ferritin on in vitro lymphocyte function. Br J Haematol.1979;42:345-353.
57. Walker EM, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci. 2000; 30:354-365.
58. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011; 53:1020–1022.
59.Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT.Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. Int J Mol Sci. 2018 Jan 8;19(1). pii: E182. doi: 10.3390/ijms19010182.
60.Finianos A, Matar CF, Taher A. Hepatocellular Carcinoma in ?-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. Int J Mol Sci. 2018 Dec 17;19(12). pii: E4070. doi: 10.3390/ijms19124070
61. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557–2576.
62. Shen FM, Lee MK, Gong HM, Cai XQ, King MC. Complex segregation analysis of primary hepatocellular carcinoma in Chinese families: interaction of inherited susceptibility and hepatitis B viral infection. Am J Hum Genet.1991;49:88–93.
63. Walker AJ, Peacock CJ, Pedergnana V; STOP-HCV Consortium, Irving WL. Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review. J Viral Hepat. 2018;25:442-456.
64. Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal AK. Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and nonalcoholic fatty liver diseases. J Clin Transl Hepatol. 2015;3:9-16.
65.Mowla A, Karimi M, Afrasiabi A, De Sanctis V. Prevalence of diabetes mellitus and impaired glucose tolerance in beta-thalassemia patients with and without hepatitis C virus infection.Pediatr Endocrinol Rev. 2004;2 (Suppl 2):282-824.
66.De Sanctis V, Soliman AT, Elsedfy H, Yaarubi SA, Skordis N, Khater D, El Kholy M, Stoeva I, Fiscina B, Angastiniotis M, Daar S, Kattamis C. The ICET-A Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients Mediterr J Hematol Infect Dis. 2016 Oct 28;8(1):e2016058.
67.Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2012;87:155-160.
68.Wankanit S, Chuansumrit A, Poomthavorn P, Khlairit P, Pongratanakul S, Mahachoklertwattana P.Acute Effects of Blood Transfusion on Insulin Sensitivity and Pancreatic ?-Cell Function in Children with ?-Thalassemia/Hemoglobin E Disease.J Clin Res Pediatr Endocrinol. 2018;10:1-7.
69.Petersen DR. Alcohol, iron-associated oxidative stress, and cancer. Alcohol. 2005;35:243–249.
70.Hu W, Feng Z, Eveleigh J, Iyer G, Pan J, Amin S, Chung FL, Tang MS. The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis. 2002;23:1781–1789.
71.Barbieri SS, Zacchi E, Amadio P, Gianellini S, Mussoni L, Weksler BB, Tremoli E. Cytokines present in smokers’ serum interact with smoke components to enhance endothelial dysfunction. Cardiovasc Res. 2011;90:475–483.
72.Díez Piña JM, Fernández Aceñero MJ, Llorente Alonso MJ, Díaz Lobato S, Mayoralas Alises S, Pérez Rodríguez E, Alvaro Álvarez D, Flórez Horcajada A, Pérez Rojo R. Tumor necrosis factor as an early marker of inflammation in healthy smokers. Med Clin (Barc). 2012;139:47–53.
73.Valenca SS, Silva Bezerra F, Lopes AA, Romana-Souza B, Marinho Cavalcante MC, Lima AB, Gonçalves Koatz VL, Porto LC. Oxidative stress in mouse plasma and lungs induced by cigarette smoke and lipopolysaccharide. Environ Res. 2008;108:199–204.
74.Purohit V, Rapaka R, Kwon OS, Song BJ. Roles of alcohol and tobacco exposure in the development of hepatocellular carcinoma. Life Sci. 2013;92:3-9.
75. Conti F, Buonfiglioli F, Scuteri A , Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727-733.
76. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, Stättermayer AF, Beinhardt S, Graziadei I, Freissmuth C, Maieron A, Gschwantler M, Strasser M, Peck-Radosalvjevic M, Trauner M, Hofer H, Ferenci P. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol. 2016;65:856-858.
77. Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, Pereira P, Lopes S, Silva M, Andrade P, Morais R, Coelho R, Macedo G. High incidence of hepatocellular carcinoma following successful interferonfree antiviral therapy for hepatitis C associated cirrhosis. J Hepatol. 2016; 65: 1070-1071.
78. Reig M, Mariño Z, Perello C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719-726.
79. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol.2016;65:734-740.
80.Adhoute X, Castellani P, Bourlière M. Impact of direct-acting antiviral agents on the risk for
hepatocellular carcinoma. Transl Gastroenterol Hepatol 2017;2:110.doi:10.21037/ tgh.2017. 12.04.
81.Soliman A, De Sanctis V, Yassin M. Vitamin d status in thalassemia major: an update.Mediterr J Hematol Infect Dis. 2013 Sep 2;5(1):e2013057. doi: 10.4084/MJHID.2013.057
82.Wu DB, Wang ML, Chen EQ, Tang H. New insights into the role of vitamin D in hepatocellular carcinoma.Expert Rev Gastroenterol Hepatol. 2018;12:287-294.
83.Louka ML, Fawzy AM, Naiem AM, Elseknedy MF, Abdelhalim AE, Abdelghany MA. Vitamin D and K signaling pathways in hepatocellular carcinoma. Gene. 2017;629:108-116.
84. Chiang KC, Yeh CN, Chen MF, Chen TC. Hepatocellular carcinoma and vitamin D: a review. J Gastroenterol Hepatol. 2011;26:1597-603.
85. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, NakatsuraT. Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. World J Gastroenterol. 2015; 21:10573-10583.
86. Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, Tsubouchi H, Kiyosawa K, Kakumu S, Okita K, Hayashi N, Okanoue T. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–1622.
87..Ryder SD; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003; 52 (Suppl 3):1–8.
88.Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment.Oncologist. 2010;15 (Suppl 4):14-22.
89. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA.Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.
90.Sciancalepore D, Zingaro MT, Luglio CV, Sabba C,Napoli N. Hepatocellular Carcinoma: Known and Emerging Risk Factors. J Cancer Ther. 2018;9:417-437.
91.Lencioni R, Piscaglia F, Bolondi L. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. J Hepatol. 2008;48:848–857.
92. Jo PC, Jang HJ, Burns PN, Burak KW, Kim TK, Wilson SR. Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how i do it. Radiology 2017;282:317- 331.
93. Nakayama Y, Inoue T, Sakamoto M, Enomoto N. Liver stiffness measurement for risk assessment of hepatocellular carcinoma. Hepatol Res. 2015;45:523-532.
94.Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68:723-750.
95.Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M, Giannini EG, Borzio F, Caturelli E, Chiaramonte M, Bernardi M; Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010; 53:291-297.
96.Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography [FibroScan(®)] with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol. 2016;22:7236-7251.